nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.08.2005 | Original Article

Comparison of gray matter and metabolic reduction in mild Alzheimer’s disease using FDG-PET and voxel-based morphometric MR studies

verfasst von: Kazunari Ishii, Hiroki Sasaki, Atsushi K. Kono, Naokazu Miyamoto, Tetsuya Fukuda, Etsuro Mori

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 8/2005

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aim of this study was to investigate regional differences between morphologic and functional changes in the same patients with mild Alzheimer’s disease (AD) using statistical parametric mapping (SPM) and voxel-based morphometry (VBM).

Methods

Thirty patients with very mild AD (mean age 66.8 years, mean MMSE score 24.0) and 30 age- and sex-matched normal volunteers underwent both¹⁸F-fluorodeoxyglucose (FDG) positron emission tomography (PET) and three-dimensional spoiled gradient echo (SPGR) magnetic resonance imaging (MRI). Statistical parametric mapping was used to conduct VBM analysis of the morphological data, which were compared voxel by voxel with the results of a similar analysis of the glucose metabolic data.

Results

In AD patients, VBM data indicated a significant gray matter volume density decrease in bilateral amygdala/hippocampus complex (p<0.05, corrected), while FDG-PET analysis showed significant glucose metabolic reductions in the posterior cingulate gyri and the right parietal lobule, compared with those in the normal control group.

Conclusion

In very mild AD, morphological change occurs in the medial temporal lobes, while in contrast, metabolic changes occur in the posterior cingulate gyri and parietal lobule.

Brun A, Englund E. Regional pattern of degeneration in Alzheimer’s disease: neuronal loss and histopathological grading. Histopathology 1981;5:549–64.

Jack CR Jr, Petersen RC, O’brien PC, Tangalos EG. MR-based hippocampal volumetry in the diagnosis of Alzheimer’s disease. Neurology 1992;42:183–8.PubMed

Grundman M, Sencakova D, Jack CR Jr, Petersen RC, Kim HT, Schultz A, et al. Alzheimer’s Disease Cooperative Study. Brain MRI hippocampal volume and prediction of clinical status in a mild cognitive impairment trial. J Mol Neurosci 2002;19:23–7.

Minoshima S, Giordani B, Barent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer’s disease. Ann Neurol 1997;42:85–94.PubMed

Hoffman JM, Welsh-Bohmer KA, Hanson M, Crain B, Hulette C, Earl N, et al. FDG PET imaging in patients with pathologically verified dementia. J Nucl Med 2000;41:1920–8.PubMed

Minoshima S. Imaging Alzheimer’s disease: clinical applications. Neuroimaging Clin North Am 2003;13:769–80.

Nordberg A. PET imaging of amyloid in Alzheimer’s disease. Lancet Neurol 2004;3:519–27.CrossRefPubMed

Ashburner J, Friston KJ. Voxel-based morphometry—the methods. Neuroimage 2000;11:805–21.CrossRefPubMed

Baron JC, Chetelat G, Desgranges B, Perchey G, Landeau B, de la Sayette V, et al. In vivo mapping of gray matter loss with voxel-based morphometry in mild Alzheimer’s disease. Neuroimage 2001;14:298–309.

Burton EJ, Karas G, Paling SM, Barber R, Williams ED, Ballard CG, et al. Patterns of cerebral atrophy in dementia with Lewy bodies using voxel-based morphometry. Neuroimage 2002;17:618–30.CrossRefPubMed

Ishii K, Sasaki M, Yamaji S, Sakamoto S, Kitagaki H, Mori E. Relatively preserved hippocampal glucose metabolism in mild Alzheimer’s disease. Dement Geriatr Cogn Disord 1998;9:317–22.

McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology 1984;34:939–44.PubMed

Berg L. Clinical dementia rating. Psychopharmacol Bull 1988;24:637–9.

Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–98.CrossRefPubMed

Honma A, Fukuzawa K, Tsukada Y, Ishii T, Hasegawa K, Mohs RC. Development of a Japanese version of Alzheimer’s Disease Assessment Scale (ADAS). Jpn J Geriatr Psychiatry 1992;3:647–55.

Ishii K, Sasaki M, Kitagaki H, Yamaji S, Sakamoto S, Matsuda K, et al. Reduction of cerebellar glucose metabolism in advanced Alzheimer’s disease. J Nucl Med 1997;38:925–8.

Friston KJ, Ashburner J, Frith CD, Poline J-B, Heather JD, Frackowiak RSJ. Spatial registration and normalization of images. Human Brain Mapping 1995;3:165–89.

Ashburner J, Neelin P, Collins DL, Evans AC, Friston KJ. Incorporating prior knowledge into image registration. Neuroimage 1997;6:344–52.CrossRefPubMed

Ashburner J, Friston KJ. Nonlinear spatial normalization using basis functions. Human Brain Mapping 1999;7:254–66.

Kesslak JP, Nalcioglu O, Cotman CW. Quantification of magnetic resonance scans for hippocampal atrophy in Alzheimer’s disease. Neurology 1991;41:51–4.

Scheltens P, Leys D, Barkhof F, Huglo D, Weinstein HC, Vermersch P, et al. Atrophy of medial temporal lobes on MRI in “probable” Alzheimer’s disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry 1992;55:967–72.

Jack CR, Petersen RC, O’Brien PC, Tangalos EG. MR-based hippocampal volumetry in the diagnosis of Alzheimer’s disease. Neurology 1992;42:183–8.PubMed

Watson C, Andermann F, Gloor P, Jones-Gotman M, Peters T, Evans A, et al. Anatomic basis of amygdaloid and hippocampal volume measurement by magnetic resonance imaging. Neurology 1992;42:1743–50.PubMed

de Leon MJ, Golomb J, George AE, Convit A, Tarshish CY, McRae T, et al. The radiologic prediction of Alzheimer’s disease: the atrophic hippocampal formation. AJNR 1993;14:897–906.

Kiliany RJ, Moss MB, Albert MS, Sandor T, Tieman J, Jolesz F. Temporal lobe regions on magnetic resonance imaging identify patients with early Alzheimer’s disease. Arch Neurol 1993;50:949–54.

Lehéricy S, Baulac M, Chiras J, Pierot L, Martin N, Pillon B, et al. Amygdalohippocampal MR volume measurements in the early stages of Alzheimer’s disease. AJNR 1994;15:927–37.

Chetelat G, Desgranges B, De La Sayette V, Viader F, Eustache F, Baron JC. Mapping gray matter loss with voxel-based morphometry in mild cognitive impairment. Neuroreport 2002;13:1939–43.

Ishii K, Sasaki M, Yamaji S, Sakamoto S, Kitagaki H, Mori E. Paradoxical hippocampus perfusion in mild-to-moderate Alzheimer’s disease. J Nucl Med 1998;39:293–8.

Ibanez V, Pietrini P, Alexander GE, Furey ML, Teichberg D, Rajapakse JC, et al. Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer’s disease. Neurology 1998;50:1585–93.

Matsuda H, Kitayama N, Ohnishi T, Asada T, Nakano S, Sakamoto S, et al. Longitudinal evaluation of both morphologic and functional changes in the same individuals with Alzheimer’s disease. J Nucl Med 2002;43:304–11.PubMed

Geddes JW, Monaghan DT, Cotman CW, Lott IT, Kim RC, Chui HC. Plasticity of hippocampal circuitry in Alzheimer’s disease. Science 1985;230:1179–81.

Hyman BT, Kromer LJ, Van Hoesen GW. Reinnervation of the hippocampal perforant pathway zone in Alzheimer’s disease. Ann Neurol 1987;21:259–67.

Ishii K, Sasaki M, Yamaji S, Sakamoto S, Kitagaki H, Mori E. Demonstration of decreased posterior cingulate perfusion in mild Alzheimer’s disease by means of H ₂ ¹⁵ O positron emission tomography. Eur J Nucl Med 1997;24:670–3.

Ishii K. Clinical application of positron emission tomography for diagnosis of dementia. Ann Nucl Med 2002;16:515–25.

Minoshima S, Foster NL, Kuhl DE. Posterior cingulate cortex in Alzheimer’s disease. Lancet 1994;344:895.CrossRef

Kogure D, Matsuda H, Ohnishi T, Asada T, Uno M, Kunihiro T, et al. Longitudinal evaluation of early Alzheimer’s disease using brain perfusion SPECT. J Nucl Med 2000;41:1155–62.PubMed

Frisoni GB, Testa C, Zorzan A, Sabattoli F, Beltramello A, Soininen H, et al. Detection of grey matter loss in mild Alzheimer’s disease with voxel based morphometry. J Neurol Neurosurg Psychiatry 2002;73:657–64.

Matsuda H, Kanetaka H, Ohnishi T, Asada T, Imabayashi E, Nakano S, et al. Brain SPET abnormalities in Alzheimer’s disease before and after atrophy correction. Eur J Nucl Med Mol Imaging 2002;29:1502–5.

Titel: Comparison of gray matter and metabolic reduction in mild Alzheimer’s disease using FDG-PET and voxel-based morphometric MR studies
verfasst von: Kazunari Ishii
Hiroki Sasaki
Atsushi K. Kono
Naokazu Miyamoto
Tetsuya Fukuda
Etsuro Mori
Publikationsdatum: 01.08.2005
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 8/2005
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-004-1740-5

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Comparison of gray matter and metabolic reduction in mild Alzheimer’s disease using FDG-PET and voxel-based morphometric MR studies

Abstract

Purpose

Methods

Results

Conclusion

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2005

Treatment of hepatocellular carcinoma by means of radiopharmaceuticals

August 2005

Biodistribution and radiation dosimetry of [11C]raclopride in healthy volunteers

Clinical axillary recurrence after sentinel node biopsy in breast cancer: a follow-up study of 220 patients

Dual-head coincidence gamma camera FDG-PET before and after autologous bone marrow mononuclear cell implantation in ischaemic stroke

The additional value of PET/CT over PET in FDG imaging of oesophageal cancer